Belépés

NCT07617441Toboroz

The Neuroanatomical and Psychological Correlates of Suggestibility in Patients With Non-Responsive Chronic Migraine

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 1.

Rövid összefoglaló (regiszter, angolul)

Chronic migraine is a disabling neurovascular disorder and one of the leading causes of years lived with disability worldwide. Population-based studies report a worrying level of resistance to currently available treatments in clinical practice. For this reason, the clinical and scientific community is increasingly investigating new therapeutic approaches aimed at reducing the burden of symptoms and improving patients' quality of life. Among the alternative therapeutic approaches explored in migraine research, the placebo effect has emerged as a potentially important mechanism. However, the duration and intensity of its beneficial effects on migraine symptoms are still poorly understood. In particular, there is a need to identify biological and clinical markers that may predict which patients are more likely to benefit from placebo-related mechanisms. One of the most promising factors is suggestibility, namely the tendency of an individual to respond to suggestions, expectations, or contextual influences. It is possible that patients with non-responsive chronic migraine may show different levels of suggestibility, which could influence the effectiveness of placebo-related responses. To investigate this hypothesis, it is first necessary to better understand the psychobiological characteristics of patients with non-responsive chronic migraine (NRCM). Therefore, the primary aim of this monocentric observational study is to characterize the neurobiological and psychological profile of individuals affected by NRCM through advanced magnetic resonance imaging techniques (connectomics) and a comprehensive battery of psychodiagnostic assessments, including the evaluation of suggestibility. The study plans to recruit at least 100 patients with NRCM and 100 healthy control subjects matched for age and sex. By comparing participants with high and low levels of suggestibility, the study aims to identify new neurobiological profiles (bio-phenotypes) associated with these characteristics. These findings may contribute to future research on the placebo effect and help develop more personalized treatment strategies for patients with chronic migraine who do not respond to conventional therapies.

Állapot (regiszter)
Toboroz
Vizsgálattípus
Megfigyeléses
Résztvevők száma
200 (tervezett)
Első benyújtás
2026. máj. 21.
Kezdés
2026. júl. 1.
Elsődleges befejezés
2028. júl.
Fő szponzor
Istituto per la Ricerca e l'Innovazione Biomedica
Betegségek
Migrén
NCT-szám
NCT07617441

Mit vállalsz

  • Vizsgálat típusa: Megfigyeléses
  • Tervezett résztvevők: 200
  • 2026. júl. 1. és az elsődleges befejezés (2028. júl.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • affected by concomitant neurological, cardiovascular, or cerebrovascular diseases;

Más betegség

  • history of alcohol or substance abuse;
  • liver disease or kidney disease;
  • psychiatric disorders (psychosis, major depression, bipolar disorder).
  • diagnosis or history of migraine (for healthy subjects).

Életkor

  • older than 75 years;

Egyéb

  • children
  • pregnant or breastfeeding women;

Kiket keres a vizsgálat

  • adults aged ≥ 18 years and ≤ 75 years;
  • diagnosis of non-responsive chronic migraine (NRCM) according to ICHD-3 beta criteria;
  • presence of at least 8 migraine days per month associated with disability (MIDAS ≥ 11), and insufficient response after 6 weeks or inability to tolerate at least three previously prescribed migraine preventive agents, i.e., resistance to standard therapy for at least 6 weeks;
  • signed informed consent.
  • adults aged ≥ 18 years and not older than 75 years;
  • absence of a diagnosis of NRCM according to ICHD3beta or other relevant -neurological disorders as assessed during the medical history taken at the headache center;
  • signed informed consent.

Életkor a regiszterben: 18 év – 75 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Renato Dulbecco University Hospital
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
CatanzaroOlaszországToboroz

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.